{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:14:32Z","timestamp":1779884072340,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ensitrelvir is a novel SARS-CoV-2 3-chymotrypsin-like protease inhibitor, similar to nirmatrelvir\/ritonavir. Several case reports have demonstrated the efficacy of 3-chymotrypsin-like protease inhibitors in treating prolonged coronavirus disease 2019 (COVID-19) in immunocompromised patients. Tacrolimus (TAC) is a widely used immunosuppressive agent whose blood level can increase significantly due to the inhibition of cytochrome P450 3A (CYP3A) and P-glycoprotein by nirmatrelvir\/ritonavir. Since ensitrelvir also inhibits CYP3A and P-gp, similar elevations in TAC levels are expected. A prior case report observed an increase in TAC trough levels with concurrent administration of ensitrelvir. However, no studies have quantitatively described the changes in TAC blood levels and clearances before and after ensitrelvir administration when TAC administration was discontinued to mitigate the drug-drug interaction (DDI) risk; data on safe dosing protocols to avoid the DDI during co-administration of ensitrelvir and TAC remain lacking. Here, we report a case in which TAC levels were successfully managed in a patient with rheumatoid arthritis (RA) who received ensitrelvir for persistent COVID-19 by preemptive discontinuation of TAC and close monitoring of TAC blood levels following ensitrelvir administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>An 81-year-old Japanese woman who had been administered TAC (1.5\u00a0mg once daily) for RA received two courses of remdesivir for moderate COVID-19. However, her viral load remained high and her respiratory status deteriorated. Considering persistent COVID-19, we initiated combination therapy with remdesivir and ensitrelvir (day 0). TAC was discontinued, and the TAC blood levels decreased from 3.6\u00a0ng\/mL to 1.1\u00a0ng\/mL over five days. Subsequently, we re-administered TAC (0.2\u00a0mg), observing a level of 1.0\u00a0ng\/mL by day 7. The TAC dose was adjusted to 1.0\u00a0mg daily, and TAC levels on day 12 and 14 were 6.5 and 3.7\u00a0ng\/mL, respectively. TAC (1.5\u00a0mg daily) was resumed on day 15. The calculated t<jats:sub>1\/2<\/jats:sub> of TAC were 33.7, 71.9, and 114.6\u00a0h from day -1 to 0, day 0 to 2, and day 2 to 5, respectively. The t<jats:sub>1\/2<\/jats:sub> of TAC was extended to 3.4-fold its original duration under ensitrelvir treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This DDI extended the half-life of TAC by approximately 3.4-fold, an effect that gradually diminished over 7 to 10\u00a0days. When patients receiving TAC treatment start ensitrelvir therapy, a dose reduction of TAC by approximately one-third to one-fourth is considered appropriate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00411-y","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T15:00:00Z","timestamp":1737558000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Yuki","family":"Miyata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ikeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"411_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-022-05522-2","volume":"613","author":"W Msemburi","year":"2023","unstructured":"Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613:130\u20137.","journal-title":"Nature"},{"key":"411_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22:449\u201375.","journal-title":"Nat Rev Drug Discov"},{"key":"411_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","volume":"76","author":"H Mukae","year":"2023","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2\/3 Study. Clin Infect Dis. 2023;76:1403\u201311.","journal-title":"Clin Infect Dis."},{"key":"411_CR4","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65:6499\u2013512.","journal-title":"J Med Chem"},{"key":"411_CR5","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40121-024-01010-4","volume":"13","author":"T Takazono","year":"2024","unstructured":"Takazono T, Fujita S, Komeda T, Miyazawa S, Yoshida Y, Kitanishi Y, et al. Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19. Infect Dis Ther. 2024;13:1821\u201333.","journal-title":"Infect Dis Ther"},{"key":"411_CR6","doi-asserted-by":"publisher","first-page":"e0063222","DOI":"10.1128\/aac.00632-22","volume":"66","author":"R Shimizu","year":"2022","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults. Antimicrob Agents Chemother. 2022;66:e0063222.","journal-title":"Antimicrob Agents Chemother"},{"key":"411_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40261-023-01309-z","volume":"43","author":"R Shimizu","year":"2023","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations. Clin Drug Investig. 2023;43:785\u201397.","journal-title":"Clin Drug Investig"},{"key":"411_CR8","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","volume":"24","author":"HM Machkovech","year":"2024","unstructured":"Machkovech HM, Hahn AM, Garonzik Wang J, Grubaugh ND, Halfmann PJ, Johnson MC, et al. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect Dis. 2024;24:e453\u201362.","journal-title":"Lancet Infect Dis"},{"key":"411_CR9","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/cid\/ciad085","volume":"76","author":"O Blennow","year":"2023","unstructured":"Blennow O, Vesterbacka J, Tovatt T, Nowak P. Successful combination treatment for persistent severe acute respiratory syndrome Coronavirus 2 infection. Clin Infect Dis. 2023;76:1864\u20135.","journal-title":"Clin Infect Dis"},{"key":"411_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/jcph.2247","volume":"63","author":"R Shimizu","year":"2023","unstructured":"Shimizu R, Matsuzaki T, Oka R, Sonoyama T, Fukuhara T, Kuwata A, et al. Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and clinical studies. J Clin Pharmacol. 2023;63:918\u201327.","journal-title":"J Clin Pharmacol"},{"key":"411_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40261-023-01265-8","volume":"43","author":"R Shimizu","year":"2023","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuzaki T, Matsuo Y, et al. Evaluation of the drug-drug interaction potential of ensitrelvir fumaric acid with cytochrome P450 3A substrates in healthy Japanese adults. Clin Drug Investig. 2023;43:335\u201346.","journal-title":"Clin Drug Investig"},{"key":"411_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1081-1206(10)62636-1","volume":"83","author":"E Letko","year":"1999","unstructured":"Letko E, Bhol K, Pinar V, Foster CS, Ahmed AR. Tacrolimus (FK 506). Ann Allergy Asthma Immunol. 1999;83:179\u201389 quiz 89-90.","journal-title":"Ann Allergy Asthma Immunol."},{"key":"411_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/0006-2952(94)90136-8","volume":"47","author":"T Shiraga","year":"1994","unstructured":"Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol. 1994;47:727\u201335.","journal-title":"Biochem Pharmacol"},{"key":"411_CR14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.transproceed.2022.04.015","volume":"54","author":"M Prikis","year":"2022","unstructured":"Prikis M, Cameron A. Paxlovid (Nirmatelvir\/Ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report. Transplant Proc. 2022;54:1557\u201360.","journal-title":"Transplant Proc"},{"key":"411_CR15","doi-asserted-by":"publisher","first-page":"ofac238","DOI":"10.1093\/ofid\/ofac238","volume":"9","author":"DT Rose","year":"2022","unstructured":"Rose DT, Gandhi SM, Bedard RA, Mondy KE, Chu AL, Gamble KC, et al. Supratherapeutic tacrolimus concentrations with Nirmatrelvir\/Ritonavir in solid organ transplant recipients requiring hospitalization: a case series using rifampin for reversal. Open Forum Infect Dis. 2022;9:ofac238.","journal-title":"Open Forum Infect Dis."},{"key":"411_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40780-024-00361-x","volume":"10","author":"H Naganawa","year":"2024","unstructured":"Naganawa H, Katada Y, Nakagawa S, Umemura K, Ishimura H, Kajiwara M, et al. Influence of ensitrelvir or nirmatrelvir\/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series. J Pharm Health Care Sci. 2024;10:37.","journal-title":"J Pharm Health Care Sci"},{"key":"411_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/17460441.2023.2267001","volume":"19","author":"S Ferraro","year":"2024","unstructured":"Ferraro S, Convertino I, Cappello E, Valdiserra G, Bonaso M, Tuccori M. Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option. Expert Opin Drug Discov. 2024;19:9\u201320.","journal-title":"Expert Opin Drug Discov"},{"key":"411_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1067\/mcp.2000.110215","volume":"68","author":"JS McCune","year":"2000","unstructured":"McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000;68:356\u201366.","journal-title":"Clin Pharmacol Ther"},{"key":"411_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"411_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2165\/00003088-200140040-00004","volume":"40","author":"PE Wallemacq","year":"2001","unstructured":"Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet. 2001;40:283\u201395.","journal-title":"Clin Pharmacokinet"},{"key":"411_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","volume":"46","author":"Y Ohno","year":"2007","unstructured":"Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46:681\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"411_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11317220-000000000-00000","volume":"48","author":"A Hisaka","year":"2009","unstructured":"Hisaka A, Kusama M, Ohno Y, Sugiyama Y, Suzuki H. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin Pharmacokinet. 2009;48:653\u201366.","journal-title":"Clin Pharmacokinet"},{"key":"411_CR23","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1111\/bcp.15835","volume":"89","author":"DS Cox","year":"2023","unstructured":"Cox DS, Rehman M, Khan T, Ginman K, Salageanu J, LaBadie RR, et al. Effects of nirmatrelvir\/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants. Br J Clin Pharmacol. 2023;89:3352\u201363.","journal-title":"Br J Clin Pharmacol"},{"key":"411_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/clpt.2008.94","volume":"84","author":"RM Franke","year":"2008","unstructured":"Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther. 2008;84:704\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"411_CR25","doi-asserted-by":"publisher","first-page":"e01201","DOI":"10.1128\/AAC.01201-17","volume":"61","author":"P Kumar","year":"2017","unstructured":"Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, et al. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic\/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017;61:e01201-e1217.","journal-title":"Antimicrob Agents Chemother"},{"key":"411_CR26","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","volume":"75","author":"S H\u00e4rtter","year":"2013","unstructured":"H\u00e4rtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(\u00ae) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"411_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF03192295","volume":"23","author":"PE Wallemacq","year":"1998","unstructured":"Wallemacq PE, Furlan V, M\u00f6ller A, Sch\u00e4fer A, Stadler P, Firdaous I, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet. 1998;23:367\u201370.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"411_CR28","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","volume":"75","author":"F Stader","year":"2020","unstructured":"Stader F, Khoo S, Stoeckle M, Back D, Hirsch HH, Battegay M, et al. Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect. J Antimicrob Chemother. 2020;75:3084\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"411_CR29","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/bcp.14292","volume":"86","author":"E Bonneville","year":"2020","unstructured":"Bonneville E, Gautier-Veyret E, Ihl C, Hilleret MN, Baudrant M, Fonrose X, et al. Unexpected overdose blood concentration of tacrolimus: Keep in mind the role of inflammation. Br J Clin Pharmacol. 2020;86:1888\u201391.","journal-title":"Br J Clin Pharmacol"},{"key":"411_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bcpt.13539","volume":"128","author":"T Enokiya","year":"2021","unstructured":"Enokiya T, Nishikawa K, Hamada Y, Ikemura K, Sugimura Y, Okuda M. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene. Basic Clin Pharmacol Toxicol. 2021;128:525\u201333.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"411_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/FTD.0b013e3181f3c063","volume":"32","author":"A Barry","year":"2010","unstructured":"Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit. 2010;32:708\u201314.","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00411-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00411-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00411-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T09:57:52Z","timestamp":1738231072000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00411-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00411-y","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient to publish this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}